Cinclus Pharma Holding AB (publ) (STO:CINPHA)
Sweden · Delayed Price · Currency is SEK | Market Cap | 562.18M +24.3% |
| Revenue (ttm) | 67.51M +1,373.9% |
| Net Income | -239.07M |
| EPS | -5.15 |
| Shares Out | 46.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 58,160 |
| Open | 12.08 |
| Previous Close | 12.08 |
| Day's Range | 11.90 - 12.20 |
| 52-Week Range | 11.72 - 19.64 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 46.25 (+288.66%) |
| Earnings Date | Aug 19, 2026 |
About Cinclus Pharma Holding AB
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori. Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquar... [Read more]
Full Company ProfileFinancial Performance
In 2025, Cinclus Pharma Holding AB's revenue was 57.47 million, an increase of 1154.80% compared to the previous year's 4.58 million. Losses were -183.97 million, 9.49% more than in 2024.
Financial StatementsNews
Cinclus Pharma Holding AB Earnings Call Transcript: Q1 2026
Lead asset linaprazan glurate advanced toward pivotal phase III results, with strong regulatory alignment and commercial launches in China. Q1 2026 saw increased R&D spending, improved cash flow, and new financing to support ongoing trials and future growth.
Cinclus Pharma Holding AB Quarterly report: Q1 2026
Cinclus Pharma Holding AB has published its Q1 2026 quarterly earnings report on May 13, 2026.
Cinclus Pharma Holding AB Slides: Q1 2026
Cinclus Pharma Holding AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Cinclus Pharma Holding AB Earnings Call Transcript: Q4 2025
Linaprazan glurate advances through phase III with strong financial backing and global partnerships, targeting blockbuster potential in severe erosive GERD. Revenue growth is driven by licensing deals, while regulatory and clinical milestones position the product for 2026 launches.
Cinclus Pharma Holding AB Quarterly report: Q4 2025
Cinclus Pharma Holding AB has published its Q4 2025 quarterly earnings report on February 18, 2026.
Cinclus Pharma Holding AB Slides: Q4 2025
Cinclus Pharma Holding AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 18, 2026.
Cinclus Pharma Holding AB Annual report: Q4 2025
Cinclus Pharma Holding AB has published its Q4 2025 annual report on February 18, 2026.
Cinclus Pharma Holding AB Transcript: KOL Event
Linaprazan glurate is poised to address major unmet needs in severe erosive GERD, offering best-in-class acid control and rapid symptom relief. The large, dynamic market supports strong commercial potential, but success will require focused marketing and differentiation among specialists.
Cinclus Pharma Holding AB Earnings Call Transcript: Q3 2025
Phase III trial for linaprazan glurate is underway with strong recruitment and positive regulatory feedback. Financials show increased R&D investment and a solid cash runway into 2027, while global PCAB market momentum supports future commercial prospects.
Cinclus Pharma Holding AB Quarterly report: Q3 2025
Cinclus Pharma Holding AB has published its Q3 2025 quarterly earnings report on November 20, 2025.
Cinclus Pharma Holding AB Slides: Q3 2025
Cinclus Pharma Holding AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 20, 2025.
Cinclus Pharma Holding AB Transcript: Stifel 2025 Healthcare Conference
Linaprazan glurate, a next-generation PCAB, is in Phase III trials targeting severe GERD patients with unmet needs, aiming for premium pricing and specialist market focus. Strong IP, a major European partnership, and a U.S. launch planned for 2029-2030 underpin the strategy.
Cinclus Pharma Holding AB Earnings Call Transcript: Q2 2025
Secured a EUR 220 million Zentiva partnership for Linaprazan glurate in Europe, with phase III trial preparations complete and imminent start. Cash position remains strong at SEK 589 million, and U.S. commercialization rights are retained for future value creation.
Cinclus Pharma Holding AB Quarterly report: Q2 2025
Cinclus Pharma Holding AB has published its Q2 2025 quarterly earnings report on August 20, 2025.
Cinclus Pharma Holding AB Slides: Q2 2025
Cinclus Pharma Holding AB has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 20, 2025.